Measles epidemiology and vaccination coverage in Oromia Region, Ethiopia: Evidence from surveillance, 2011-2018. 2021

Kiddus Yitbarek, and Tizta Tilahun, and Tessema Debela, and Dereje Abdena, and Tsinuel Girma
Department of Health Policy and Management, Jimma University, Jimma, Ethiopia. Electronic address: kiddus.yitbarek@yahoo.com.

Despite a reported high coverage of measles-containing vaccine (MCV), low-income countries including, Ethiopia, have sustained high measles transmission with frequent outbreaks. We investigated the distribution of measles infection and vaccination in Oromia Regional State, Ethiopia. According to the World Health Organization (WHO) and the Ethiopian measles case classification guidelines, measles cases were classified as laboratory-confirmed, clinically compatible, and epidemiologically linked. We derived measles vaccination coverage estimates using reported measles vaccine efficacy and, the proportion of measles cases vaccinated with measles vaccine at least once from the surveillance data. We calculated measles effective reproduction number (Re) in the region. Almost twenty-five thousand measles cases were reported through the surveillance system, with more than 50% of the suspected and confirmed measles cases reported in 2015. Measles had sustained and high transmission rate with uneven distribution among the zones. Children between 1 and 4 years of age and MCV unvaccinated individuals were the most affected groups. In all the zones, the average surveillance-estimated MCV coverage among both infants and under-five children was significantly lower than the WHO recommended minimum 90% threshold herd-immunity. With this level of vaccination coverage, an infected case can transmit to more than four individuals. Nevertheless, the administrative coverage reports for the concurrent period were consistently above 90%. The estimated MCV coverage across the Oromia region was well below the recommended herd-immunity threshold. It partly explains the apparent mismatch of sustained measles transmission and outbreaks despite the very high administrative coverage estimates. Oromia regional health bureau, in collaboration with key stakeholders, should make a concerted effort to increase the effective-coverage of MCV to at least 90%. Additionally, multiple-dose MCV has to be scaled-up and accompanied with appropriate geographic and age targeting using evidence from surveillance data. Immediate programmatic action is needed to improve the quality of measles surveillance.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008457 Measles A highly contagious infectious disease caused by MORBILLIVIRUS, common among children but also seen in the nonimmune of any age, in which the virus enters the respiratory tract via droplet nuclei and multiplies in the epithelial cells, spreading throughout the MONONUCLEAR PHAGOCYTE SYSTEM. Rubeola
D008458 Measles Vaccine A live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had measles or been immunized with live measles vaccine and have no serum antibodies against measles. Children are usually immunized with measles-mumps-rubella combination vaccine. (From Dorland, 28th ed) Vaccine, Measles
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D004196 Disease Outbreaks Sudden increase in the incidence of a disease. The concept includes EPIDEMICS and PANDEMICS. Outbreaks,Infectious Disease Outbreaks,Disease Outbreak,Disease Outbreak, Infectious,Disease Outbreaks, Infectious,Infectious Disease Outbreak,Outbreak, Disease,Outbreak, Infectious Disease,Outbreaks, Disease,Outbreaks, Infectious Disease
D005002 Ethiopia An independent state in eastern Africa. Ethiopia is located in the Horn of Africa and is bordered on the north and northeast by Eritrea, on the east by Djibouti and Somalia, on the south by Kenya, and on the west and southwest by Sudan. Its capital is Addis Ababa. Federal Democratic Republic of Ethiopia
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000073887 Vaccination Coverage Rate of VACCINATION as defined by GEOGRAPHY and or DEMOGRAPHY. Immunization Coverage,Coverage, Immunization,Coverage, Vaccination,Coverages, Immunization,Coverages, Vaccination,Immunization Coverages,Vaccination Coverages
D014611 Vaccination Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis. Immunization, Active,Active Immunization,Active Immunizations,Immunizations, Active,Vaccinations

Related Publications

Kiddus Yitbarek, and Tizta Tilahun, and Tessema Debela, and Dereje Abdena, and Tsinuel Girma
January 2020, The Pan African medical journal,
Kiddus Yitbarek, and Tizta Tilahun, and Tessema Debela, and Dereje Abdena, and Tsinuel Girma
January 2017, The Pan African medical journal,
Kiddus Yitbarek, and Tizta Tilahun, and Tessema Debela, and Dereje Abdena, and Tsinuel Girma
March 2024, Vaccine,
Kiddus Yitbarek, and Tizta Tilahun, and Tessema Debela, and Dereje Abdena, and Tsinuel Girma
November 2019, BMC research notes,
Kiddus Yitbarek, and Tizta Tilahun, and Tessema Debela, and Dereje Abdena, and Tsinuel Girma
January 2020, Tropical medicine and health,
Kiddus Yitbarek, and Tizta Tilahun, and Tessema Debela, and Dereje Abdena, and Tsinuel Girma
November 2021, Vaccine,
Kiddus Yitbarek, and Tizta Tilahun, and Tessema Debela, and Dereje Abdena, and Tsinuel Girma
January 2021, Infection and drug resistance,
Kiddus Yitbarek, and Tizta Tilahun, and Tessema Debela, and Dereje Abdena, and Tsinuel Girma
January 2022, Veterinary medicine international,
Kiddus Yitbarek, and Tizta Tilahun, and Tessema Debela, and Dereje Abdena, and Tsinuel Girma
January 2022, Infection and drug resistance,
Kiddus Yitbarek, and Tizta Tilahun, and Tessema Debela, and Dereje Abdena, and Tsinuel Girma
July 2019, BMC research notes,
Copied contents to your clipboard!